+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Methicillin-Resistant Staphylococcus Aureus Drugs Market by Primary Segmentation - Global Forecast to 2030- Product Image
Methicillin-Resistant Staphylococcus Aureus Drugs Market by Primary Segmentation - Global Forecast to 2030- Product Image
Sale

Methicillin-Resistant Staphylococcus Aureus Drugs Market by Primary Segmentation - Global Forecast to 2030

  • PDF Icon

    Report

  • 181 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 4968650
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Senior executives navigating the evolving pharmaceutical landscape face critical decisions amid rising antimicrobial resistance. The methicillin-resistant Staphylococcus aureus (MRSA) drugs market demands strategic insight, as novel therapeutic innovations and shifting regulatory, geographic, and economic factors reshape commercial opportunities and risks.

Market Snapshot: Methicillin-Resistant Staphylococcus Aureus Drugs Market

The Methicillin-Resistant Staphylococcus Aureus Drugs Market grew from USD 2.21 billion in 2024 to USD 2.36 billion in 2025. It is expected to continue growing at a CAGR of 6.46%, reaching USD 3.22 billion by 2030. As persistent resistance to existing antibiotics challenges patient care globally, companies must address pricing, regulatory dynamics, and competitive positioning to capture value and drive long-term growth in this segment.

Scope & Segmentation

This report provides comprehensive benchmarking and strategic frameworks across the following critical segments and regions:

  • Administration Route: Intravenous and oral formulations address both acute inpatient and outpatient therapeutic needs.
  • Approval Status: Includes both approved MRSA agents and pipeline candidates categorized in phase I, II, and III, highlighting evolving innovation cycles.
  • Distribution Channel: Encompasses supply to hospital pharmacies and retail pharmacies for diverse access points.
  • Drug Class: Covers glycopeptides, lipoglycopeptides, lipopeptides, and oxazolidinones, illustrating therapeutic diversity and mechanisms of action.
  • End User: Serves ambulatory surgical centers, clinics, and hospitals, offering insight into procurement and usage environments.
  • Indication: Addresses bacteremia, endocarditis, pneumonia, and skin and soft tissue infections, reflecting high clinical burden areas.
  • Geographic Regions: Analysis across Americas, Europe, Middle East & Africa, and Asia-Pacific, with deep dives on country-level dynamics such as the United States, China, Germany, and others.
  • Key Companies: Strategic profiling of industry leaders, including Merck & Co., Pfizer, Allergan, Johnson & Johnson, Novartis, Astellas, Theravance Biopharma, Paratek Pharmaceuticals, Melinta Therapeutics, and Tetraphase Pharmaceuticals.

These segmentation layers are vital in formulating tailored go-to-market strategies and understanding the interplay between clinical settings, drug access, and regulatory climates.

Key Takeaways: Strategic Insights for Decision-Makers

  • The market is shaped by the transition toward innovative drug classes such as lipoglycopeptides and lipopeptides, enabling more potent and convenient therapies for MRSA.
  • Firms must adapt to evolving regulatory frameworks that prioritize expedited access to breakthrough antimicrobials, influencing clinical development planning and time-to-market.
  • Operational agility in supply chain management, particularly through investments in local manufacturing, is essential to mitigating risks associated with changing global trade policies.
  • Market segmentation by administration route and end user enables companies to align product portfolios with the needs of acute care and community health settings, optimizing revenue streams.
  • Regional variations in reimbursement, regulatory oversight, and competitive intensity require nuanced, data-driven commercialization approaches for sustainable growth.

Tariff Impact: Navigating New Cost Structures and Competitiveness

The 2025 adjustments to US import tariffs on active pharmaceutical ingredients are increasing production costs and intensifying the focus on alternative sourcing, supply chain resilience, and local manufacturing. These changes are driving companies to reevaluate pricing negotiations and reimbursement strategies, while variations in international trade barriers are prompting new approaches to market entry and competition. Such factors have direct implications for profitability and market penetration in both established and emerging regions.

Methodology & Data Sources

This research synthesizes primary qualitative interviews with industry leaders and clinical experts, alongside comprehensive secondary analysis of regulatory filings, company reports, and peer-reviewed sources. Quantitative modeling correlates external drivers, such as policy changes and pipeline evolution, to market trends, with findings validated through data triangulation for robust, executive-ready strategic guidance.

Why This Report Matters

  • Enables stakeholders to navigate complex regulatory environments and evolving treatment paradigms with actionable intelligence.
  • Supports data-driven resource allocation and risk mitigation by providing granular segmentation and competitive analysis.
  • Guides investment and partnership decisions through detailed evaluation of market outlook, innovation pipelines, and reimbursement dynamics.

Conclusion

The MRSA drugs market landscape is characterized by scientific advancements, operational shifts, and regional nuances. Aligning strategy to these dynamics enables organizations to accelerate innovation, address unmet medical needs, and drive sustainable value in a competitive and rapidly changing environment.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Methicillin-Resistant Staphylococcus Aureus Drugs Market, by Primary Segmentation
8.1. Introduction
8.2. Administration Route
8.2.1. Intravenous
8.2.2. Oral
8.3. Approval Status
8.3.1. Approved
8.3.2. Pipeline
8.3.2.1. Phase I
8.3.2.2. Phase II
8.3.2.3. Phase III
8.4. Distribution Channel
8.4.1. Hospital Pharmacy
8.4.2. Retail Pharmacy
8.5. Drug Class
8.5.1. Glycopeptides
8.5.2. Lipoglycopeptides
8.5.3. Lipopeptides
8.5.4. Oxazolidinones
8.6. End User
8.6.1. Ambulatory Surgical Centers
8.6.2. Clinics
8.6.3. Hospitals
8.7. Indication
8.7.1. Bacteremia
8.7.2. Endocarditis
8.7.3. Pneumonia
8.7.4. Skin and Soft Tissue Infection
9. Americas Methicillin-Resistant Staphylococcus Aureus Drugs Market
9.1. Introduction
9.2. United States
9.3. Canada
9.4. Mexico
9.5. Brazil
9.6. Argentina
10. Europe, Middle East & Africa Methicillin-Resistant Staphylococcus Aureus Drugs Market
10.1. Introduction
10.2. United Kingdom
10.3. Germany
10.4. France
10.5. Russia
10.6. Italy
10.7. Spain
10.8. United Arab Emirates
10.9. Saudi Arabia
10.10. South Africa
10.11. Denmark
10.12. Netherlands
10.13. Qatar
10.14. Finland
10.15. Sweden
10.16. Nigeria
10.17. Egypt
10.18. Turkey
10.19. Israel
10.20. Norway
10.21. Poland
10.22. Switzerland
11. Asia-Pacific Methicillin-Resistant Staphylococcus Aureus Drugs Market
11.1. Introduction
11.2. China
11.3. India
11.4. Japan
11.5. Australia
11.6. South Korea
11.7. Indonesia
11.8. Thailand
11.9. Philippines
11.10. Malaysia
11.11. Singapore
11.12. Vietnam
11.13. Taiwan
12. Competitive Landscape
12.1. Market Share Analysis, 2024
12.2. FPNV Positioning Matrix, 2024
12.3. Competitive Analysis
12.3.1. Merck & Co., Inc.
12.3.2. Pfizer Inc.
12.3.3. Allergan plc
12.3.4. Johnson & Johnson
12.3.5. Novartis AG
12.3.6. Astellas Pharma Inc.
12.3.7. Theravance Biopharma, Inc.
12.3.8. Paratek Pharmaceuticals, Inc.
12.3.9. Melinta Therapeutics, Inc.
12.3.10. Tetraphase Pharmaceuticals, Inc.
13. ResearchAI
14. ResearchStatistics
15. ResearchContacts
16. ResearchArticles
17. Appendix
List of Figures
FIGURE 1. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET MULTI-CURRENCY
FIGURE 2. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PRIMARY SEGMENTATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PRIMARY SEGMENTATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 10. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 12. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 18. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PRIMARY SEGMENTATION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY APPROVAL STATUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY APPROVED, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PIPELINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PIPELINE, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOGLYCOPEPTIDES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INDICATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY BACTEREMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ENDOCARDITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PNEUMONIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PRIMARY SEGMENTATION, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PIPELINE, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PRIMARY SEGMENTATION, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PIPELINE, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 58. CANADA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PRIMARY SEGMENTATION, 2018-2030 (USD MILLION)
TABLE 59. CANADA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 60. CANADA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 61. CANADA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PIPELINE, 2018-2030 (USD MILLION)
TABLE 62. CANADA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 63. CANADA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 64. CANADA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 65. CANADA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 66. MEXICO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PRIMARY SEGMENTATION, 2018-2030 (USD MILLION)
TABLE 67. MEXICO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 68. MEXICO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 69. MEXICO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PIPELINE, 2018-2030 (USD MILLION)
TABLE 70. MEXICO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 71. MEXICO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 72. MEXICO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 73. MEXICO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PRIMARY SEGMENTATION, 2018-2030 (USD MILLION)
TABLE 75. BRAZIL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 77. BRAZIL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PIPELINE, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PRIMARY SEGMENTATION, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PIPELINE, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PRIMARY SEGMENTATION, 2018-2030 (USD MILLION)
TABLE 91. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 92. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 93. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PIPELINE, 2018-2030 (USD MILLION)
TABLE 94. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 96. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 99. UNITED KINGDOM METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PRIMARY SEGMENTATION, 2018-2030 (USD MILLION)
TABLE 100. UNITED KINGDOM METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 101. UNITED KINGDOM METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 102. UNITED KINGDOM METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PIPELINE, 2018-2030 (USD MILLION)
TABLE 103. UNITED KINGDOM METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 104. UNITED KINGDOM METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 105. UNITED KINGDOM METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 106. UNITED KINGDOM METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 107. GERMANY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PRIMARY SEGMENTATION, 2018-2030 (USD MILLION)
TABLE 108. GERMANY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 109. GERMANY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 110. GERMANY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PIPELINE, 2018-2030 (USD MILLION)
TABLE 111. GERMANY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 112. GERMANY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 113. GERMANY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 114. GERMANY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 115. FRANCE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PRIMARY SEGMENTATION, 2018-2030 (USD MILLION)
TABLE 116. FRANCE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 117. FRANCE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 118. FRANCE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PIPELINE, 2018-2030 (USD MILLION)
TABLE 119. FRANCE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 120. FRANCE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 121. FRANCE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 122. FRANCE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 123. RUSSIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PRIMARY SEGMENTATION, 2018-2030 (USD MILLION)
TABLE 124. RUSSIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 125. RUSSIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 126. RUSSIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PIPELINE, 2018-2030 (USD MILLION)
TABLE 127. RUSSIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 128. RUSSIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 129. RUSSIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 130. RUSSIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 131. ITALY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PRIMARY SEGMENTATION, 2018-2030 (USD MILLION)
TABLE 132. ITALY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 133. ITALY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 134. ITALY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PIPELINE, 2018-2030 (USD MILLION)
TABLE 135. ITALY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 136. ITALY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 137. ITALY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 138. ITALY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 139. SPAIN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PRIMARY SEGMENTATION, 2018-2030 (USD MILLION)
TABLE 140. SPAIN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 141. SPAIN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 142. SPAIN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PIPELINE, 2018-2030 (USD MILLION)
TABLE 143. SPAIN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 144. SPAIN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 145. SPAIN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 146. SPAIN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 147. UNITED ARAB EMIRATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PRIMARY SEGMENTATION, 2018-2030 (USD MILLION)
TABLE 148. UNITED ARAB EMIRATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 149. UNITED ARAB EMIRATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 150. UNITED ARAB EMIRATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PIPELINE, 2018-2030 (USD MILLION)
TABLE 151. UNITED ARAB EMIRATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 152. UNITED ARAB EMIRATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 153. UNITED ARAB EMIRATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 154. UNITED ARAB EMIRATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 155. SAUDI ARABIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PRIMARY SEGMENTATION, 2018-2030 (USD MILLION)
TABLE 156. SAUDI ARABIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 157. SAUDI ARABIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 158. SAUDI ARABIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PIPELINE, 2018-2030 (USD MILLION)
TABLE 159. SAUDI ARABIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 160. SAUDI ARABIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 161. SAUDI ARABIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 162. SAUDI ARABIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 163. SOUTH AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PRIMARY SEGMENTATION, 2018-2030 (USD MILLION)
TABLE 164. SOUTH AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 165. SOUTH AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 166. SOUTH AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PIPELINE, 2018-2030 (USD MILLION)
TABLE 167. SOUTH AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 168. SOUTH AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 169. SOUTH AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 170. SOUTH AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 171. DENMARK METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PRIMARY SEGMENTATION, 2018-2030 (USD MILLION)
TABLE 172. DENMARK METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 173. DENMARK METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 174. DENMARK METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PIPELINE, 2018-2030 (USD MILLION)
TABLE 175. DENMARK METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 176. DENMARK METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 177. DENMARK METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 178. DENMARK METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 179. NETHERLANDS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PRIMARY SEGMENTATION, 2018-2030 (USD MILLION)
TABLE 180. NETHERLANDS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 181. NETHERLANDS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 182. NETHERLANDS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PIPELINE, 2018-2030 (USD MILLION)
TABLE 183. NETHERLANDS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 184. NETHERLANDS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 185. NETHERLANDS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 186. NETHERLANDS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 187. QATAR METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PRIMARY SEGMENTATION, 2018-2030 (USD MILLION)
TABLE 188. QATAR METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 189. QATAR METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 190. QATAR METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PIPELINE, 2018-2030 (USD MILLION)
TABLE 191. QATAR METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 192. QATAR METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 193. QATAR METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 194. QATAR METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 195. FINLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PRIMARY SEGMENTATION, 2018-2030 (USD MILLION)
TABLE 196. FINLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 197. FINLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 198. FINLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PIPELINE, 2018-2030 (USD MILLION)
TABLE 199. FINLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 200. FINLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 201. FINLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 202. FINLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 203. SWEDEN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PRIMARY SEGMENTATION, 2018-2030 (USD MILLION)
TABLE 204. SWEDEN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 205. SWEDEN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 206. SWEDEN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PIPELINE, 2018-2030 (USD MILLION)
TABLE 207. SWEDEN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 208. SWEDEN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 209. SWEDEN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 210. SWEDEN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 211. NIGERIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PRIMARY SEGMENTATION, 2018-2030 (USD MILLION)
TABLE 212. NIGERIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 213. NIGERIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 214. NIGERIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PIPELINE, 2018-2030 (USD MILLION)
TABLE 215. NIGERIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 216. NIGERIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 217. NIGERIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 218. NIGERIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 219. EGYPT METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PRIMARY SEGMENTATION, 2018-2030 (USD MILLION)
TABLE 220. EGYPT METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 221. EGYPT METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 222. EGYPT METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PIPELINE, 2018-2030 (USD MILLION)
TABLE 223. EGYPT METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 224. EGYPT METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 225. EGYPT METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 226. EGYPT METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 227. TURKEY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PRIMARY SEGMENTATION, 2018-2030 (USD MILLION)
TABLE 228. TURKEY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 229. TURKEY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 230. TURKEY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PIPELINE, 2018-2030 (USD MILLION)
TABLE 231. TURKEY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 232. TURKEY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 233. TURKEY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 234. TURKEY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 235. ISRAEL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PRIMARY SEGMENTATION, 2018-2030 (USD MILLION)
TABLE 236. ISRAEL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 237. ISRAEL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 238. ISRAEL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PIPELINE, 2018-2030 (USD MILLION)
TABLE 239. ISRAEL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 240. ISRAEL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 241. ISRAEL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 242. ISRAEL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 243. NORWAY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PRIMARY SEGMENTATION, 2018-2030 (USD MILLION)
TABLE 244. NORWAY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 245. NORWAY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 246. NORWAY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PIPELINE, 2018-2030 (USD MILLION)
TABLE 247. NORWAY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 248. NORWAY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 249. NORWAY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 250. NORWAY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 251. POLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PRIMARY SEGMENTATION, 2018-2030 (USD MILLION)
TABLE 252. POLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 253. POLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 254. POLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PIPELINE, 2018-2030 (USD MILLION)
TABLE 255. POLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 256. POLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 257. POLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 258. POLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 259. SWITZERLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PRIMARY SEGMENTATION, 2018-2030 (USD MILLION)
TABLE 260. SWITZERLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUR

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Methicillin-Resistant Staphylococcus Aureus Drugs market report include:
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Allergan plc
  • Johnson & Johnson
  • Novartis AG
  • Astellas Pharma Inc.
  • Theravance Biopharma, Inc.
  • Paratek Pharmaceuticals, Inc.
  • Melinta Therapeutics, Inc.
  • Tetraphase Pharmaceuticals, Inc.

Table Information

Report AttributeDetails
No. of Pages181
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 2.36 Billion
Forecasted Market Value ( USD ) by 2030 $ 3.22 Billion
Compound Annual Growth Rate6.4%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Report 2025 - Product Image

Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Methicillin-Resistant Staphylococcus Aureus Infections - Pipeline Insight, 2025 - Product Image

Methicillin-Resistant Staphylococcus Aureus Infections - Pipeline Insight, 2025

  • Drug Pipelines
  • 100 Pages
  • Global
From
Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections - Pipeline Insight, 2025 - Product Image

Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs - Global Strategic Business Report - Product Image

Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs - Global Strategic Business Report

  • Report
  • 194 Pages
  • Global
From
Methicillin-resistant Staphylococcus Aureus (MRSA) Epidemiology Forecast 2025-2034 - Product Image

Methicillin-resistant Staphylococcus Aureus (MRSA) Epidemiology Forecast 2025-2034

  • Report
  • 150 Pages
  • Global
From

About the MRSA Drug Market

Methicillin-resistant Staphylococcus aureus (MRSA) is a type of bacteria that is resistant to many antibiotics. As a result, it is a major cause of infections in hospitals and other healthcare settings. To combat this, the MRSA drug market has developed a range of treatments, including antibiotics, antiseptics, and vaccines. These drugs are designed to target the bacteria and reduce the risk of infection. The MRSA drug market is highly competitive, with a range of companies offering different treatments. Some of the major players in the market include Pfizer, Merck, GlaxoSmithKline, Sanofi, and Novartis. These companies are constantly developing new treatments to combat the spread of MRSA and other infectious diseases. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.